Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Vivoryon Therapeutics NV FCF Yield % Related Terms
Vivoryon Therapeutics NV FCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XAMS:VVY vs VRTX, REGN, ALNY: FCF Yield % Comparison
For the Biotechnology subindustry, Vivoryon Therapeutics NV's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivoryon Therapeutics NV FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vivoryon Therapeutics NV's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Vivoryon Therapeutics NV's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vivoryon Therapeutics NV (XAMS:VVY) has a FCF Yield % of -24.63 as of Jul. 20, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Vivoryon Therapeutics NV and its competitors. According to the industry distribution chart, Vivoryon Therapeutics NV ranks #985 out of 1409 companies in the Biotechnology industry, placing it in the top 69.9%.
Is Vivoryon Therapeutics NV's FCF Yield % too high?
Vivoryon Therapeutics NV's current FCF Yield % is -24.63. Based on the distribution chart, Vivoryon Therapeutics NV ranks #985 out of 1409 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Vivoryon Therapeutics NV has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Vivoryon Therapeutics NV's FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vivoryon Therapeutics NV ranks #985 out of 1409 companies for FCF Yield %. This places Vivoryon Therapeutics NV in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Vivoryon Therapeutics NV and its competitors. Vivoryon Therapeutics NV's current FCF Yield % is -24.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivoryon Therapeutics NV stock overvalued right now?
Vivoryon Therapeutics NV (XAMS:VVY) has a current FCF Yield % of -24.63. The current FCF Yield % is -24.63. Vivoryon Therapeutics NV's overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Vivoryon Therapeutics NV (XAMS:VVY), the current FCF Yield % is -24.63 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vivoryon Therapeutics NV is a clinical-stage biopharmaceutical company focused on discovering, developing, and potentially commercializing small-molecule-based medicines that modulate the activity and stability of pathologically altered proteins. Vivoryon is currently focused on developing treatments for chronic kidney disease (CKD), and more precisely, is initially targeting stage 3b and worse diabetic kidney disease (DKD). Its product pipeline includes various drug candidates, including varoglutamstat (PQ912), VY2149, and NCE, as potential treatments for chronic kidney disease (CKD), and more precisely, are initially targeting stage 3b and worse diabetic kidney disease (DKD). The company is also pursuing antibody-based approaches for Alzheimer's disease.
25GF Score
Get the complete analysis for XAMS:VVY
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XAMS:VVY has been successfully added to your 
